2-(2,6-dichlorobenzyl)pyrimidine | 1285711-93-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,6-dichlorobenzyl)pyrimidine
• 英文别名: 2-[(2,6-Dichlorophenyl)methyl]pyrimidine
• CAS: 1285711-93-4
• 化学式: C₁₁H₈Cl₂N₂
• 分子量: 239.104
• InChiKey: VSVUDRYSEUMXKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(2,6-二氯苯基)-乙脒 、 1,2,3-三嗪 以 乙腈 为溶剂， 反应 2.08h， 以90%的产率得到2-(2,6-dichlorobenzyl)pyrimidine
  参考文献：
  名称：

  1,2,3-三嗪的逆向电子需求 Diels-Alder 反应：取代基对反应性和环加成范围的显着影响

  摘要：

  公开了对 1,2,3-三嗪的逆电子需求 Diels-Alder 反应的系统研究，包括对 C5 取代基影响的检查。发现此类取代基对 1,2,3-三嗪的环加成反应性表现出显着影响，而不会改变甚至可能增强固有的环加成区域选择性。该研究表明，反应性不仅可以通过 C5 取代基（R = CO(2)Me > Ph > H）可预测地调节，而且其影响对于转化 1,2,3-三嗪 (1)及其适度的环加成范围进入杂环氮杂二烯体系，其反应范围预示着广泛的合成效用，扩大了参与亲二烯体的范围。值得注意的是，这些研究定义了现在强大的附加杂环氮杂二烯，

  DOI：

  10.1021/ja204856a

文献信息

• Scope of the Inverse Electron Demand Diels–Alder Reactions of 1,2,3-Triazine
  作者：Erin D. Anderson、Dale L. Boger

  DOI：10.1021/ol2007428

  日期：2011.5.6

  An examination of the scope of the inverse electron demand Diels–Alder reactions of the parent unsubstituted 1,2,3-triazine is described including the first report of its unique capabilities for participating in previously unexplored [4 + 2] cycloaddition reactions with heterodienophiles.

  描述了对母体未取代的 1,2,3-三嗪的逆电子需求 Diels-Alder 反应范围的检查，包括其参与先前未探索的 [4 + 2] 环加成反应与亲异二烯体的独特能力的第一份报告。
• PIPERIDINE/PIPERAZINE DERIVATIVES
  申请人：Janssen Pharmaceutica NV

  公开号：US20170029440A1

  公开（公告）日：2017-02-02

  The invention further relates to a DGAT inhibitor of formula including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —NR x —C(═O)—; —Z—C(═O)—; —Z—NR x —C(═O)—; —S(═O)p-; —C(═S)—; —NR x —C(═S)—; —Z—C(═S)—; —Z—NR x —C(═S)—; —O—C(═O)—; —C(═O)—C(═O)—; R 1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted; R 2 represents R 3 ; R 3 represents C 3-6 cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C 3 - 6 cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzo-dioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or 6-membered aromatic heterocycle may optionally be substituted; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
• DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST
  申请人：Janssen Pharmaceutica NV

  公开号：US20180028660A1

  公开（公告）日：2018-02-01

  The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.
• US9688696B2
  申请人：——

  公开号：US9688696B2

  公开（公告）日：2017-06-27
• US9724418B2
  申请人：——

  公开号：US9724418B2

  公开（公告）日：2017-08-08